SCHEMBL7246149

SCHEMBL7246149

CC(C)CCNCc1ccc[c]c1CCC(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.38
MPO P05164 4/20 0.33
POLB P06746 1/20 0.33
CYP2C19 P33261 1/20 0.33
CHRM2 P08172 2/20 0.33
CA12 O43570 3/20 0.33
CA2 P00918 3/20 0.33
ITGB1 P05556 1/20 0.32
ITGA4 P13612 1/20 0.32
ITGB7 P26010 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
SLC6A4 P31645 1/20 0.32
ALDH1A1 P00352 1/20 0.31
CA9 Q16790 2/20 0.31
KDM4E B2RXH2 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5110715 0.91 KCNA5 (0.34) KCNA5MPOCHRM2CA12CA2
SCHEMBL5096949 0.88 CHRM2 (0.36) KCNA5MPOCYP2C19CHRM2CA12
SCHEMBL5111043 0.88 GAA (0.34) KCNA5MPOSLC6A4TSHR
SCHEMBL7247978 0.88 CA2 (0.34) KCNA5MPOCYP2C19CA2ALDH1A1
SCHEMBL5104181 0.87 HRH4 (0.39) CYP2C19CHRM2CA12CA2CA9
SCHEMBL5096779 0.86 CHRM2 (0.40) CHRM2CA12CA2CA9TSHR
SCHEMBL5110869 0.84 SLC6A4 (0.32) SLC6A4
SCHEMBL7250851 0.83 BCHE (0.37) ALDH1A1
SCHEMBL5100688 0.82 SLC6A2 (0.36) SLC6A4
SCHEMBL7249252 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627624-B1 Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, NEUROGEN CORPORATION 2003-09-30 US disclosed